Status: Formulation development underway

 

​

• Around 40% of all cancer patients receive chemotherapy, of whom approximately 65% develop hair loss as a result.

 

• In addition, a majority of patients who receive radiation therapy to the head region develop hair loss.

 

• Existing “Cold cap” solutions require special equipment and lengthy treatment times, and are associated with scalp pain

 

• NG12 represents a faster-acting, topical pharmaceutical solution with substantial quality of life benefits.